To characterize EGFR downstream signaling that may correlate with the synergistic inhibitory effects of cetuximab and cisplatin on colon cancer cell growth, we examined whether combination treatment with cetuximab and cisplatin affected EGFR and its downstream signaling pathway. The gene discussed is EGFR; the disease is colonic neoplasm.